Merakris Therapeutics' MTX-001 Selected as Finalist for Advanced Wound Care Innovation Showcase
Key Insights
Merakris Therapeutics (search)' amniotic fluid-derived regenerative biologic MTX-001 was selected as one of only six finalists for the 2025 Advanced Wound Care Summit Innovation Showcase.
MTX-001 aims to become the first subcutaneous biologic drug therapy for chronic non-healing venous leg ulcers (search), representing a new class of regenerative biologics.
The company is currently conducting a Phase 2 clinical trial with promising interim results and plans to advance to Phase 3 trials.
Merakris Therapeutics (search) announced that its investigational amniotic fluid-derived regenerative biologic, MTX-001, has been selected as a finalist for the Innovation Showcase: Early-Stage Disruptors in Wound Care at the 2025 Advanced Wound Care Summit in Boston. Only six companies were chosen by the AWC selection committee to present at the event on July 17, 2025.
Novel Subcutaneous Biologic Therapy
MTX-001 represents a potentially groundbreaking approach to treating chronic non-healing venous leg ulcers (search) (VLUs), also referred to as venous stasis ulcers (search) (VSUs). The investigational drug aims to become the first subcutaneous biologic drug therapy specifically designed for this challenging condition.
"Non-healing VLUs affect millions of people and a substantial number of patients fail to heal with today's standard therapies," said Chris Broderick, Merakris Therapeutics (search) CEO. "MTX-001 represents a new class of regenerative biologics delivered via subcutaneous injection. This innovation is proving to promote healing in chronic venous wounds and improve patient outcomes."
Clinical Development Progress
At the Innovation Showcase, Broderick will present an overview of MTX-001, including promising key findings from the ongoing Phase 2 clinical trial evaluating the therapy in patients with non-healing venous leg ulcers (search). The company has reported interim Phase 2 results showing encouraging outcomes for this novel therapeutic approach.
Sean O'Connell, PhD, Head of Medical Affairs at Merakris Therapeutics (search), will also present at the summit on July 16th at 3:15pm with a talk titled "Injectable Drugs as the Next Big Step for Advanced Wound Care." His presentation will review the MTX-001 clinical program, interim Phase 2 results, and outline upcoming plans for a Phase 3 clinical trial.
Addressing Unmet Medical Needs
O'Connell's presentation will highlight the significant unmet needs in the chronic wound market and discuss the emerging role of injectable biologics in outpatient care. The company positions MTX-001 as addressing a critical gap in current treatment options for patients with chronic venous wounds.
Company Background
Merakris Therapeutics (search) describes itself as a leading innovator in regenerative medicine focused on developing and commercializing biologically derived products for wound healing and other complex conditions. The company leverages advanced biologic manufacturing capabilities and maintains a robust research pipeline committed to improving patient outcomes and advancing regenerative therapy science.
The investigational drug has alternative tradenames including Dermacyte Liquid or Dermacyte Amniotic Wound Care Liquid (search), though it has not yet received FDA approval. Merakris offers an Expanded Access Program for MTX-001 and is actively seeking strategic partnership and collaboration opportunities.